C1A 

C1A is a class I/II HDACs and sirtuin inhibitor with an IC₅₀ of 479 nM for HDAC6. C1A induces sustained acetylation of HDAC6 substrates, α-tubulin and HSP90. C1A shows srtong anticancer effcts, and induces apoptosis in cancer cells^[1].

C1A (2.5-10 μM; 24 h) increases the sub-G1 population in a drug concentration-related manner. And C1A induces apoptosis and inhibits proliferation of a panel of human tumour cell lines from different origins in the low micromolar range^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

C1A (20-40 mg/kg; ip; once a day, twice a day, once every two days; for 14 days) inhibits the growth of colon tumours in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

498.42

C₂₂H₂₅Cl₂N₃O₄S

1021463-02-4

ClCCN(C1=CC=C(C=C1)S(NC2=CC=C(C=C2)/C=C(C)/C=C/C(NO)=O)(=O)=O)CCCl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. M Kaliszczak, et al. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth. Br J Cancer. 2013 Feb 5;108(2):342-50.  [Content Brief]